Table 3.
Multivariable model of risk factors for developing ICB during V-V ECMO treatment. The tested variables were different between the groups before starting V-V ECMO, or additionally became different during ECMO treatment. Odds Ratios (OR) were calculated after dichotomizing the variables. The ICB group’s median was used as the cut-off value. Delta values indicate a difference between pre-cannulation values and values 2 h after starting V-V ECMO. CI95%: 95% confidence interval. Additional multivariable models, univariable calculations and number of patients at risk are summarized in Supplementary Table S6.
| Multivariable regression analysis model delta paCO2, delta norepinephrine, platelets <100/nl | |||
|---|---|---|---|
| Odds ratio | CI95% | p-value | |
| Creatinine >1.5mg/dl Before ECMO treatment |
1.09 | 0.53–2.34 | 0.812 |
| aPTT > 45s Before ECMO treatment |
1.09 | 0.57–2.08 | 0.793 |
| Platelets <100/nl Before ECMO treatment |
2.64 | 1.26–5.53 | 0.01 |
| Blood-urea >100 mg/dl Before ECMO treatment |
1.35 | 0.67–2.71 | 0.404 |
| LDH >550 U/L Before ECMO treatment |
1.60 | 0.82–3.11 | 0.170 |
| Delta paCO2 >35mmHg | 4.85 | 2.16–10.88 | <0.001 |
| Delta norepinephrine >1mg/h | 1.70 | 0.90–3.21 | 0.103 |
| ASAT > 80U/L Before ECMO treatment |
0.79 | 0.39–1.61 | 0.512 |
| SOFA score | 0.92 | 0.83–1.02 | 0.126 |
| pH before ECMO treatment | 0.03 | 0.001–0.745 | 0.032 |
SOFA: Sequential organ failure assessment; aPTT: activated partial Thromboplastin-Time; ASAT: Aspartat-Aminotransferasis; LDH: Lactate-Dehydrogenasis; V-V ECMO: Veno-venous extracorporeal membrane oxygenation.